Edwards Lifesciences Corp (EW)

Working capital turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 5,724,300 5,872,600 5,999,100 6,143,400 6,004,800 5,819,000 5,657,100 5,500,800 5,382,400 5,363,800 5,355,000 5,357,100 5,232,500 5,094,500 4,925,200 4,474,200 4,386,300 4,368,700 4,321,800 4,483,700
Total current assets US$ in thousands 6,285,400 6,727,700 4,516,000 4,170,500 4,035,700 4,067,500 3,647,000 3,257,200 3,095,800 3,513,900 3,263,100 3,241,300 3,180,700 3,515,500 3,322,900 3,069,200 3,091,000 2,980,400 2,690,300 2,507,900
Total current liabilities US$ in thousands 1,505,200 1,944,100 1,217,000 1,110,800 1,195,400 1,238,900 1,157,200 1,082,000 1,022,400 917,900 969,100 949,900 1,032,300 966,500 886,200 799,000 893,900 846,300 873,200 746,900
Working capital turnover 1.20 1.23 1.82 2.01 2.11 2.06 2.27 2.53 2.60 2.07 2.33 2.34 2.44 2.00 2.02 1.97 2.00 2.05 2.38 2.55

December 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $5,724,300K ÷ ($6,285,400K – $1,505,200K)
= 1.20

The working capital turnover of Edwards Lifesciences Corp has shown fluctuating trends over the period under consideration. The ratio peaked at 2.60 as of December 31, 2022, indicating that the company was able to generate $2.60 in revenue for every dollar of working capital invested. This suggests efficient utilization of its working capital during that period.

However, the working capital turnover ratio started declining after December 2022, reaching a low of 1.20 by December 31, 2024. This downward trend indicates a potential decrease in the company's efficiency in generating revenue from its working capital.

Overall, it is essential for Edwards Lifesciences Corp to continuously monitor and manage its working capital effectively to ensure optimal operational performance and sustainable growth in the long run.


See also:

Edwards Lifesciences Corp Working Capital Turnover (Quarterly Data)